SIEN Sientra

Sientra Supports Breast Cancer Awareness Month by Launching Educational Programs Designed to Empower Women

Sientra Supports Breast Cancer Awareness Month by Launching Educational Programs Designed to Empower Women

Sientra Partners with Breast Cancer Survivor, Miranda McKeon, to Encourage Women to Take Charge of Their Breast Reconstruction Journey

SANTA BARBARA, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced the launch of several initiatives in honor of Breast Cancer Awareness Month. as part of their long-standing commitment to breast cancer awareness and education Sientra has partnered with actress and breast cancer survivor, Miranda McKeon; collaborated with the Brem Foundation to launch “Sientra Supports”; and continues to support Reshaping Lives: Full Circle.

Miranda McKeon, a 20-year-old breast cancer survivor diagnosed with stage three breast cancer in June 2021, has partnered with Sientra to help raise awareness around the importance of education and research when making tough personal choices about breast cancer treatment and reconstruction options. Miranda is using her platform to share her breast cancer journey and share the research she did to find her board-certified plastic surgeon and the Sientra implants used for her reconstruction.

“I want women to know they have choices when it comes to reconstruction,” said McKeon. “When I finally chose my surgeon, I appreciated that she spent a lot of time explaining why Sientra was her implant of choice. Sientra has an unrivaled safety profile1 and the most comprehensive and longest warranty of any breast implant manufacturer in the U.S. This is extremely important to me - I’m young and I’ve got a long life to live.”

In addition, Sientra has also partnered with the , a non-profit organization that seeks to maximize women’s chances of finding early, curable breast cancer through education, access, and advocacy, to launch Sientra Supports. This nationwide program will support Brem Foundation’s Re-Bra program by providing women who have undergone breast augmentation or breast reconstruction the opportunity to donate gently used pre-surgery bras to low-income women in need.  

Sientra Supports donation boxes will be available in board-certified plastic surgeon’s offices across the country, encouraging the donation of gently used bras. To further expand on their philosophy of giving back, Sientra employees will come together in a corporate give-back day to tag the donated bras with educational information about early breast cancer detection and materials from , on how to receive reconstructive care from board-certified volunteer plastic surgeons across the country if the need arises.

“Sientra is rooted in its philosophy of giving back to the community,” said Ron Menezes, President and CEO of Sientra. “We are committed to increasing access to education for the early detection of breast cancer and broaden awareness of reconstruction options available to the nearly 300,000 women in this country who are diagnosed with invasive breast cancer every year.”

All these programs are in addition to Sientra’s large-scale support of , a nationwide program aimed at providing free reconstructive breast surgery for post-mastectomy women living in poverty across the U.S. 

“I am happy to partner with Sientra to spread the word about breast cancer awareness, education and access to reconstructive surgical care,” said Miranda. “I am proof that early detection saves lives, and that you can thrive after a mastectomy and reconstruction surgery.”

About Sientra

Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at .

References:

  1. Stevens WG, Calobrace MB, Alizadeh A, Zeidler KR, Harrington JL, d’Incelli RC. Ten-year core study data for Sientra’s Food and Drug Administration—approved round and shaped breast implants with cohesive silicone gel. Plast Reconstr Surg. 2018;141(4S):7S-19S.



Sientra Contact:

Media

EvolveMKD

 



EN
03/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sientra

 PRESS RELEASE

Sientra Announces Completion and Winning Bidders of its Section 363 Sa...

Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra’s breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra’s BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (“Sientra” or the “Company”) announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC (“Tiger”) has been declared t...

 PRESS RELEASE

Sientra to Pursue Strategic Sale of its Business Through Voluntary Cha...

Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on F...

 PRESS RELEASE

Sientra Reports Third Quarter Financial and Operational Results

Sientra Reports Third Quarter Financial and Operational Results IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, a...

 PRESS RELEASE

Sientra to Present at the Stifel 2023 Healthcare Conference

Sientra to Present at the Stifel 2023 Healthcare Conference IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its participation at the Stifel 2023 Healthcare Conference. As part of the conference, the company’s management team will participate in a live fireside chat on Wednesday, November 15, 2023 at 8:00am EST / 5:00am PST. An on-demand webcast of the presentation will be accessible under “News & Ev...

 PRESS RELEASE

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Res...

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch